

1 Case Report

2  
3 Implementation of a Rapid RT-LAMP Saliva-based SARS-CoV-2 Testing Program in the Workplace

4 Bradley W.M. Cook <sup>1\*</sup>, Kaitlyn Kobasa <sup>1,†</sup>, Marielou Tamayo <sup>1,†</sup>, Natasha Theriault <sup>1,2,†</sup>, Diane Gordon Pappas  
5 <sup>1</sup>,  
6 Steven S. Theriault <sup>1,2</sup>

7 <sup>1</sup> Cytophage Technologies Inc., Winnipeg, Manitoba, Canada, R3Y 1G4

8 <sup>2</sup> Department of Microbiology, The University of Manitoba, Winnipeg, Manitoba, Canada, R3T 2N2

9 <sup>†</sup> These authors have contributed equally to this work

10 \* Correspondence: [bcook@cytophage.com](mailto:bcook@cytophage.com)

11 **Abstract** Rising SARS-CoV-2 cases, testing delays and the risk of pre-symptomatic and asymptomatic  
12 transmission provided the impetus for an in-house rapid testing program. Employees and their household  
13 contacts were encouraged to self-collect saliva samples which were pooled for routine testing using an es-  
14 tablished colorimetric reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay. In  
15 brief, individual or a maximum of four saliva samples were pooled, heat-inactivated to render microorgan-  
16 isms, especially SARS-CoV-2, non-infectious prior to being added to RT-LAMP assay tubes containing either  
17 human sample control gene, RNase P or a region of the SARS-CoV-2 gene, ORF1ab. During the second wave  
18 of SARS-CoV-2 infections in November 2020, two samples from an employee and a member of their  
19 household tested positive via RT-LAMP within two days of each other. A delayed clinical qRT-PCR test  
20 confirmation of both individuals 5 days later underscores the power of routine rapid testing with with-  
21 in-the-hour turnaround times. Workplace rapid testing programs using RT-LAMP are flexible in their design,  
22 have a reduced cost compared to qRT-PCR, may involve non-invasive self-saliva collection for increased  
23 safety for the testing personnel, and can be performed with minimal training.

24 **Keywords** SARS-CoV-2; COVID-19; Rapid Molecular Testing; RT-LAMP; Diagnostics; Occupational  
25 Health and Safety; group testing; self-administration test

26 **Introduction**

27 Quantitative reverse-transcription-polymerase chain reaction (qRT-PCR) is recognized as the gold  
28 standard diagnostic test to determine if an individual is infected with SARS-CoV-2. Samples are obtained  
29 from a nasopharyngeal swab or the less invasive, nasal swab. This test strategy requires costly and sometimes  
30 supply limited consumables, hours of skilled labor, and expensive machinery for testing and analysis [1]. All  
31 of which are typically not available outside of clinical settings or an established academic laboratory. During  
32 the summer of 2020 in Manitoba, Canada the demand for qRT-PCR testing led to processing delays and ex-  
33 tended turnaround times- up to several days for results [2]–[4]. Long turnaround times would exacerbate  
34 community spread as testing is voluntary and positive results would be skewed towards symptomatic indi-  
35 viduals [5], in Manitoba more than two-thirds submitted for testing were symptomatic (summarized in Figure  
36 1). This bias meant that 20-59% of infected individuals which are either pre-symptomatic or asymptomatic  
37 were unobserved by public health authorities and may have led to further transmission [6], [7]. The public  
38 health impact of such delays, necessitate the use of cheap, easy-to-manufacture, scalable and affordable rapid  
39 testing options which can aid in the ability to pre-screen for potentially contagious individuals. Rapid tests can

40 be performed without highly trained personnel or complicated machinery (end point is detected visually) and  
41 are amenable for rapid daily-use to detect contagious individuals [1]. Reverse transcription loop-mediated  
42 isothermal amplification (RT-LAMP) is a rapid testing technique which amplifies target gene(s) resulting in  
43 continual amplification of stem-loop DNA structures at a single temperature [8]. The assay for SARS-CoV-2  
44 detection used in this screening program was previous optimized by Yang et. al. 2020, for use with acidic  
45 saliva samples and a limit of detection (LOD) of 200 virions/ $\mu\text{L}$  (Ct of  $\sim 30$ ) [9]. We hypothesized that routine  
46 RT-LAMP testing would significantly decrease the opportunity for workplace transmission of SARS-CoV-2.  
47 We endeavored on a 9 month-long prescreening program for laboratory staff and on occasion included  
48 household contacts.

## 49 **Materials and Methods**

### 50 **Study Design**

51 The premise of the testing regime was to prevent or reduce the likelihood of workplace transmission  
52 especially during times when high demand would result in qRT-PCR testing/results delays. Employees were  
53 asked to remain home if they or family members were sick and asked for voluntary collection of a contact-less  
54 saliva sample for testing. While at the workplace, non-pharmaceutical interventions such as physical dis-  
55 tancing, masking and frequent handwashing were adhered to, in compliance with local public health orders  
56 [10]. A 3-testing-days-a-week (generally Monday, Wednesday, Friday and included Tuesday or Thursdays in  
57 lieu of an observed holiday) plan was implemented to voluntarily test employees prior to beginning work.  
58 Outlier samples from friends and family were sporadically accepted. Employees were given a unique identi-  
59 fication number by random draw, this number was used throughout the testing period, then 2 to 4 employee  
60 samples were pooled as a group with a letter designation. Outlier samples were given a unique number and  
61 were either tested individually or were pooled with other outliers to comprise a unique and separate letter  
62 group. The program commenced on September 16, 2020 and concluded on May 31, 2021. Positive group  
63 pools were disaggregated and individually retested (referred to as reflex testing) with all three SARS-CoV-2  
64 RT-LAMP primer sets to determine a true positive. Test-positive individuals were asked to leave the work-  
65 place and follow the Manitoba Public Health Guidelines regarding isolation and visit an official COVID-19  
66 Testing Centre for qRT-PCR testing. Pending qRT-PCR confirmation of a positive result employees adhered  
67 to return to work policies set by Manitoba public health [11]. Figure 2 demonstrates expected results for the  
68 screening program.

### 69 **Saliva-sample preparation**

70 Sample tube master mix preparation. Sample tubes were prepared with 2X Stabilization buffer, as de-  
71 scribed previously [9]. Briefly, a stock containing: 5mM (717 mg) TCEP-HCl (Gold Bio #TCEP10, Cedarlane  
72 Labs, Burlington, Canada), 2mM (2 mL) 0.5M pH8 EDTA (#324506-100ML, Millipore-Sigma, Oakville,  
73 Canada), 29mM (1.45 mL) 10M NaOH pellets (#S8045-500G, Millipore-Sigma, Oakville, Canada) previ-  
74 ously dissolved in nuclease-free water, 100  $\mu\text{g}/\text{mL}$  (50mg) recombinant PCR-grade Proteinase K (Roche  
75 #3115879001, Cedarlane Labs, Burlington, Canada) and then the solution was brought up to 500 mL with  
76 nuclease-free water (10220-404, VWR, Mississauga, Canada). One mL aliquots of 2X Stabilization buffer  
77 were deposited into nuclease-free, graduated, 5 mL screw-cap sample tubes (#10002-738, VWR, Mississauga,  
78 Ontario, Canada) and stored at 4°C until use. Saliva-sampling. On scheduled testing days, employees were  
79 asked to abstain from consuming any food, beverages or brushing teeth half an hour prior to producing a  
80 sample. The employees would independently remove a sample tube-containing 1 mL 2X Stabilization buffer  
81 from 4°C and provide 1 mL of fresh saliva from an isolated location: then tubes were shaken vigorously for 10  
82 seconds, labeled with their respective unique number identifier, the exterior was decontaminated with 70%  
83 ethanol for 60 seconds at room temperature then stored at 4°C in a designated location [12], [13]. Samples  
84 were generally processed for the LAMP assay within a few hours; however, samples may be stored for up to 4

85 days [9].

86

## 87 **Saliva-sample processing**

88 Sample tubes were vortexed briefly, then heat-inactivated in water baths (thermometer-verified) for 10  
89 minutes at 95°C. Tubes were then plunged in ice and transferred into a biological safety cabinet for LAMP  
90 assay preparation.

## 91 **Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) Assay**

92 **Primers.** Desalted primer sets were fabricated by IDT (Coralville, Iowa, USA), according to the se-  
93 quences provided previously by Yang et. al. [9]. Primer sets were diluted and mixed to make 10X concen-  
94 tration of primers targeting different regions in the SARS-CoV-2 genome: the ORF1ab gene (A1SE and  
95 ORF1e) or the N gene (N2) and, a control for human saliva (RNaseP) that detects the RNase P gene. A1SE,  
96 ORF1e, N2 and RNaseP primer sets contained: FIB and BIP (16 µM), LF and LB (4 µM) and F3 and B3 (2  
97 µM) primers, except LF was omitted from N2. The sequences are provided in Supplementary Table S1.

98 **RT-LAMP assay master mix.** Reactions were prepared as independent master mixes as described  
99 previously [9]. Briefly, 4 µL of nuclease-free water, 10 µL Warmstart colorimetric LAMP 2X master mix  
100 (#M1800L, New England Biolabs, Whitby, Canada) and 2 µL respective 10X primer set mix (either AS1E,  
101 ORF1e, N2 or RNase P) were combined and aliquoted into PCR tubes. For routine testing only the AS1E  
102 reactions were used for randomly pooled saliva samples and virus controls and only 1 group at random was  
103 tested for RNase P. For test reactions, either 4 µL from an individual's saliva-stabilization buffer sample or an  
104 equal division of up to four saliva-stabilization samples was added but never exceeded four pooled samples (1  
105 µL each) per group. Negative control and SARS-CoV-2 positive control reactions were prepared similarly,  
106 except four µL nuclease-free water in 2X stabilization buffer or 4 µL of SARS-CoV-2 control virus, were  
107 added instead of saliva. The 20 µL reactions were gently vortex and incubated in a thermal cycler at 65°C for  
108 30 minutes, but never exceeded 35 minutes, followed by heat inactivation for 2 minutes at 80°C to preserve to  
109 color and prevent further unwanted amplification. Reaction tubes were visually inspected for color-change  
110 due to pH changes during amplification of viral RNA (basic pH-pink color: negative and acidic pH-yellow  
111 color: positive) and documented, immediately after heat inactivation. In the event of a positive test, the group  
112 was split into individual samples and tested with all primer sets along with the appropriate negative and virus  
113 controls.


114 **SARS-CoV-2 virus controls.** Two microliters from a stock of  $1.6 \times 10^5$  TCID<sub>50</sub>/mL ( $1.8 \times 10^8$  RNA  
115 genome copies/mL) heat-inactivated SARS-CoV-2 (2019-nCoV/USA/WA1/2020, ATCC VR-1986HK,  
116 #2225411, Cedarlane Labs, Burlington, Canada) was aliquoted into nuclease-free 0.2 mL PCR tubes (Axygen  
117 Scientific PCR-02-C, #10011-780, VWR, Mississauga, Canada) equating to approximately 320 TCID<sub>50</sub> units  
118 ( $3.6 \times 10^5$  RNA genome copies) and stored at -80°C. An aliquot was added to a saliva-sample tube containing:  
119 1 mL 2X stabilization buffer and 1 mL nuclease-free water (in place of saliva), heat-inactivated (10 minutes at  
120 95°C), cooled on ice (5 minutes) and 4 µL were added to reaction tubes, approximately equivalent to 0.64  
121 TCID<sub>50</sub> units (720 RNA genome copies) of SARS-CoV-2.

## 122 **Results**

123 During the 9-month screening program, n= 1,649 saliva samples were tested with 2 positive cases de-  
124 tected, both were from the same household (percent positivity: 0.12%). The epidemiological curve of reported  
125 COVID-19 positive cases in Manitoba during the study period is summarized in Figure 1. Two surges in


126 observed cases occurred from November 8 to November 28 and May 9 to May 22 (Figure 1). During the  
127 November case surge, on the evening of a regular workday (herein referred to as “Day 1”, an employee, re-  
128 ferred herein as “E” (who tested negative earlier that morning on the scheduled testing day) reported that a  
129 loved one had a “scratchy throat” (herein referred to as “F”). E was asked not to report for work on the fol-  
130 lowing day (Day 2); however, E and F delivered samples contactless for non-scheduled testing. E tested  
131 negative, and F tested positive with the AS1E primer set. F was retested with appropriate controls and was  
132 found to be positive again with AS1E and with ORF1e, but not with N2 (Figure 3 (a)). Both E and F attempted  
133 to isolate from each other at home and immediately scheduled an appointment for qRT-PCR at a COVID-19  
134 Testing Centre. However, since the earliest available was days later (Day 5), the decision was made that E  
135 should not report to work. On the next regularly scheduled testing day (Day 3), E again was negative, and F  
136 remained positive (Figure 3 (b)). On Day 4, a non-scheduled testing day, E became positive with the AS1E  
137 primer set and was not retested with any other primer sets. Additionally, F did not provide a sample (Figure 3  
138 (c)). On Day 5, E and F were administered nasopharyngeal swabs and subsequently tested by qRT-PCR, both  
139 were confirmed positive 2 days later (Day 7). E and F complied with Manitoba Public Health’s recommen-  
140 dations and E returned to work when the isolation period had officially ended on Day 17, as summarized in  
141 Figure 4.

142




143


144 **Figure 1.** Epidemiological data of qRT-PCR positive cases in Manitoba from September 13, 2020 to June 5,  
145 2021. Data was compiled from Manitoba’s Provincial COVID-19 Surveillance System  
146 (<https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/index.html>) presented as a rolling average  
147 of two-week case counts. Every two-week interval included in the analysis reported the percentage of indi-  
148 viduals which were symptomatic at the time of testing (73.9% (+/- 3.2)). An overall average was calculated  
149 from each two-week interval.



150 **Figure 2.** Expected RT-LAMP Reaction Results. (a) Control saliva-sample tubes were mixed 1:1 with Sta-  
 151 bilization buffer and nuclease-free water, spiked with 2  $\mu$ L of heat-inactivated SARS-CoV-2 or with 2  $\mu$ L  
 152 nuclease-free water, as indicated, and incubated for 10 minutes at 95°C. Four  $\mu$ L of respective mixtures were  
 153 added to RT-LAMP reactions with SARS-CoV-2 primer sets (AS1E, N2 or ORF1e) and incubated for 30  
 154 minutes at 65°C followed by 2 minutes at 80°C. Images were taken on a lightbox with 4X (top panel) and 10X  
 155 (bottom panel) magnification. (b) Saliva-sample tubes were mixed 1:1 with Stabilization buffer and saliva or  
 156 nuclease-free water, as indicated, and incubated for 10 minutes at 95°C. RT-LAMP reactions with the RNase  
 157 P primer set were prepared, four  $\mu$ L of the respective mixtures were added and incubated for 30 minutes at  
 158 65°C followed by 2 minutes at 80°C. Images were taken on a lightbox with 4X (top panel) and 10X (bottom  
 159 panel) magnification. A negative amplification of the gene target results in the solution to remain pink (basic  
 160 pH) whereas, target gene amplification results in a color change from pink to yellow (acidic pH).



162 **Figure 3.** Original RT-LAMP Test Results from Individual's E and F. (a) Day 2: individual F's saliva sample  
 163 processed and subjected to RT-LAMP using AS1E, N2 and ORF1e primer sets against SARS-CoV-2. (b) Day  
 164 3: individual E and F's saliva were tested using AS1E per a regular scheduled testing day. (c) Day 4: indi-  
 165 vidual E's saliva sample was deemed positive with AS1E primer set against SARS-CoV-2. PC –  
 166 SARS-CoV-2 virus control, SC – Saliva control (RNase P), NC – Negative control, AS1E, N2 and ORF1e –  
 167 primer sets targeting SARS-CoV-2 genes. A negative amplification of the gene target results in the solution to  
 168 remain pink (basic pH) whereas, target gene amplification results in a color change from pink to yellow (acidic  
 169 pH).



170

171 **Figure 4.** Timeline of E and F cases. Beginning on Day 1, individual E tested negative for SARS-CoV-2. Day  
 172 2 saliva samples for E and F were subjected to RT-LAMP using AS1E. Upon F testing positive, the sample  
 173 retested positive with AS1E and ORF1e but not for the N2 primer sets against SARS-CoV-2. E and F  
 174 scheduled an appointment for qRT-PCR testing. On Day 3, E tested negative, and F remained positive. On  
 175 Day 4, E’s saliva sample was positive for SARS-CoV-2 with the AS1E primer set and further testing was  
 176 omitted. Day 5 and Day 7: E and F received qRT-PCR tests and were confirmed positive, respectively. A  
 177 positive test for SARS-CoV-2 is represented in yellow with a “+” and a negative test is denoted in pink with  
 178 “-”.

## 179 Discussion

180 We describe a simple and cost-effective program that can be applied in the workplace or other private  
 181 setting to screen for SARS-CoV-19 infection and recommend employees or their close contacts for clinical  
 182 diagnostic testing. The results from screening (around 15 to 20 samples per test day) employees and their  
 183 friends and family members, demonstrate that frequent testing can identify infectious individuals and limit the  
 184 spread of SARS-CoV-2. Although during the 9-month program, only 2 samples were positive for  
 185 SARS-CoV-2, public health measures in Manitoba cycled between aggressive lockdowns and slightly relaxed  
 186 restrictions. Undoubtedly, public health interventions played a role in the decreased case prevalence. In retros-  
 187 pect, given the increasing caseloads, one could have anticipated higher case numbers in the workplace,  
 188 especially during the epidemiological week of the 2 positive samples (November 1, 2020 to November 7,  
 189 2020). The province’s testing and positivity rate increased by 1.1%, a change of n=1,451 administered tests  
 190 and n=1,019 more positive cases were observed compared to 1 incubation period earlier (October 18 - 24,  
 191 2020) [14], [15]. Moreover, the delays in testing (3 days) and results (2 days) as experienced by E and F could  
 192 have led to transmission in the workplace and possibly at employee residences or in public settings.

193 The choice to collect saliva specimens instead of nasal or nasopharyngeal swabs include ease-of-use  
 194 (self-collection), enhanced safety of testing personnel and an increased likelihood of compliance. Numerous  
 195 reports corroborate that molecular detection of SARS-CoV-2 from saliva samples does not significantly differ  
 196 from the diagnostic accuracy of nasopharyngeal swabs [16]–[18] especially during the prodromal phase or in  
 197 asymptomatic individuals [16], [19]. A scheme that prioritizes saliva over swabs would be more amenable for  
 198 routine testing in children. This would be very powerful as children, despite tending to display milder  
 199 symptoms or remaining asymptomatic when compared to adults [20], may shed infectious virus at similar  
 200 levels [21], [22].

201 Direct saliva testing with the Warmstart product in relation to hydrolysis-probe qRT-PCR, demonstrated  
 202 a limit of detection (LOD) of 200 virions/μL (Ct of ~ 30) [9] and 100-1000 viral RNA copies (in vitro tran-  
 203 scribed RNA) (Ct of ~ 30 ± 2.6). Thus, Warmstart appears to be 10 to 100 times less sensitive than

204 qRT-PCR [23]. Of note, the sensitivity of RT-LAMP can be improved using alternative enzymes, reagents,  
205 dye preparations and an optional RNA extraction step, as demonstrated after the conclusion of our study [23].  
206 Differences in sensitivity between RT-LAMP and qRT-PCR has been shown in to be comparable when testing  
207 frequency was daily, every three and every seven days in epidemiologic modeling [5]. Thus, the strategy of  
208 increased testing frequency can overcome lower sensitivity with the additional benefits of: non-invasive  
209 sample collection, lower cost, availability, and consistency when detecting highly contagious individuals ( $Ct$   
210  $< \sim 30 - 32$ ) in real-world settings [9], [23]. It is worth noting that these authors used different primer sets for  
211 their RT-LAMP studies and that  $Ct$  values may vary based on the choice of hydrolysis-probes, reagent  
212 chemistries and machine variability.

213 Variants were not documented by the Manitoba government until the week of February 7 to February 13,  
214 2021 (epidemiological week 6) from then onwards to the end of the study, the predominant variants were:  
215 either “undefined” or were B.1.1.7. (Alpha) in approximately 5 - 30% of cases depending on the week [24].  
216 Using the Global Initiative on Sharing Avian Flu Data (GISAID) initiative, we compared the primer set se-  
217 quence fidelity (AS1E, ORF1e and N2) to the first variant described during the study period. In chronological  
218 order the Beta, Alpha, Gamma and Delta variants were identified on samples collected on January 21, 2021  
219 (accession: EPI\_ISL\_1594283), January 16, 2021 (accession: EPI\_ISL\_1594098), March 31, 2021 (acces-  
220 sion: EPI\_ISL\_1594071) and April 29, 2021 (accession: EPI\_ISL\_2495627), respectively (Supplementary  
221 Table S2). Additionally, the Lambda and Mu variants were not detected prior to June 1, 2021. The AS1E  
222 primers remained identical to Alpha, Beta, Gamma and Delta. However, the F3 from the ORF1e set had a  
223 single nucleotide change (C to T) in Alpha only. More importantly, the N2 primer set had two primers: Loop B  
224 and FIP that had multiple changes. Loop B had a single difference (G to T) when compared to Delta. Whereas  
225 FIP demonstrated 3, 5 and 1 nucleotide changes for Alpha, Gamma and Delta, respectively (Supplementary  
226 Table S2). In the context F’s saliva sample testing negative with N2: even though Alpha was not documented  
227 until January, it is unclear if Alpha may have been circulating during late October. While it is tempting to  
228 speculate that an infection with Alpha may have caused this failure, it is more likely a false negative.

229 The potential for false negative reporting is a limitation of the study: i) screening for a at least 2 or 3 gene  
230 targets instead of 1 (AS1E) would decrease the likelihood of a false negative. ii) RNaseP detection was only  
231 performed in 1 group per scheduled testing day. It is possible that some saliva samples may be lacking an  
232 adequate concentration of buccal cells for each group, indicating poor sample collection.

## 233 Conclusions

234 During a nine-month, voluntary SARS-CoV-2 testing program, two positive samples out of nearly  $n=$   
235 1700 were identified and confirmed by subsequent tests. This type of program helps disseminate the  
236 knowledge that inexpensive, convenient, primers can be adjusted for new variants for routine rapid testing for  
237 SARS-CoV-2. These assays can be accomplished in under an hour with minimal expertise and with reduced  
238 risks to the test administrator in multiple settings including, workplaces and schools.

239 **Supplementary Materials** Table S1: primer sets for RT-LAMP assay and nucleotide changes observed in  
240 variants, Table S2: GISAID sequences used in study.

241 **Author Contributions** BWMC and SST conceived and designed the testing program. DGP coordinated or-  
242 dering of supplies and generating protocols. BWMC and DGP optimized the RT-LAMP assay including virus  
243 controls. KK, MT, and NT performed the routine RT-LAMP testing and results documentation. BWMC in-  
244 terpreted data and wrote the manuscript. All authors provided feedback and editing. All authors have read and  
245 agreed to the published version of the manuscript.

246 **Author Disclaimer** Conclusions or learnings were not gained through research (for wide external application)  
247 but through a QI/QA project carried out in the local context.

248 **Funding** This research received no external funding.

249 **Institutional Review Board Statement** Ethical review and approval were waived for this study, due to a  
250 non-human subjects research determination and ethical evaluation which was deemed ineligible for Institu-  
251 tional Review Board review by Sterling IRB, protocol number 9576.

252 **Informed Consent Statement** Informed consent was obtained from all subjects involved in the study.  
253 Written informed consent has been obtained from the patient(s) to publish this paper.

254 **Data Availability Statement** Manitoba's epidemiological data can be obtained from the "Epidemiological &  
255 Surveillance Unit" provided by the Government of Manitoba  
256 (<https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/index.html>). Positive test case data from  
257 routine testing is contained within the manuscript (Figure 1, Figure 3 and Figure 4) and in supplementary  
258 material (Table S1 and Table S2). Data available on request due to privacy and ethical restrictions. Official  
259 testing results documents presented in this study are available on request from the corresponding author. The  
260 data are not publicly available due to the privacy of the documents.

261 **Acknowledgments** We would like to acknowledge the collection and submitting laboratories which shared  
262 SARS-CoV-2 variant sequences with GISAID (Supplementary Table S2).

263 **Conflicts of Interest** The authors declare no conflict of interest. The funders had no role in the design of the  
264 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision  
265 to publish the results.

## 266 **References**

- 267 1. M. J. Mina, R. Parker, and D. B. Larremore, "Rethinking Covid-19 Test Sensitivity — A Strategy for  
268 Containment," *N. Engl. J. Med.*, p. NEJMp2025631, Sep. 2020, doi: 10.1056/NEJMp2025631.
- 269 2. C. MacLean, "With days-long waits for results, some Winnipeg parents question value of getting  
270 COVID-19 tests," *Canadian Broadcasting Corporation (CBC) News*, 2020, Oct. 17, 2020.
- 271 3. J. Keele, "Results for COVID-19 test times seeing delays as cases grow in Manitoba," *Canadian Tele-*  
272 *vision Network (CTV) News*, May 04, 2021.
- 273 4. P. Lam, "Frustrated Manitobans say they're waiting days for COVID-19 test results," *Canadian*  
274 *Broadcasting Corporation (CBC) News*, Winnipeg, Oct. 07, 2020.
- 275 5. D. B. Larremore et al., "Test sensitivity is secondary to frequency and turnaround time for COVID-19  
276 screening," *Sci. Adv.*, vol. 7, no. 1, pp. 1–10, 2021, doi: 10.1126/sciadv.abd5393.
- 277 6. M. A. Johansson et al., "SARS-CoV-2 Transmission from People without COVID-19 Symptoms,"  
278 *JAMA Netw. Open*, vol. 4, no. 1, pp. 1–8, 2021, doi: 10.1001/jamanetworkopen.2020.35057.
- 279 7. A. L. Rasmussen and S. V. Popescu, "SARS-CoV-2 transmission without symptoms," *Science (80-. )*,  
280 vol. 371, no. 6535, pp. 1206–1207, 2021, doi: 10.1126/science.abf9569.
- 281 8. T. Notomi et al., "Loop-mediated isothermal amplification of DNA.," *Nucleic Acids Res.*, vol. 28, no.  
282 12, p. E63, Jun. 2000, doi: 10.1093/nar/28.12.e63.
- 283 9. Q. Yang et al., "Saliva TwoStep for rapid detection of asymptomatic SARS-CoV-2 carriers," *Elife*, vol.  
284 10, no. e65113, pp. 1–28, 2021, doi: 10.7554/eLife.65113.
- 285 10. M. Government, "General COVID-19 Prevention Orders," *Winnipeg*, 2020. doi:  
286 10.1016/S0140-6736(02)63253-2.

- 287 11. P. H. Manitoba, “COVID-19 Novel Coronavirus Guidelines: Key Responsibilities of Employees, Man-  
288 agers and Employers,” 2020. [Online]. Available: [https://www.gov.mb.ca/asset\\_library/en/coronavirus/workplace\\_responsibilities.pdf](https://www.gov.mb.ca/asset_library/en/coronavirus/workplace_responsibilities.pdf).
- 289 12. G. Xiling et al., “In vitro inactivation of SARS-CoV-2 by commonly used disinfection products and  
290 methods,” *Sci. Rep.*, vol. 11, no. 1, pp. 1–9, 2021, doi: 10.1038/s41598-021-82148-w.
- 291 13. A. Kratzel et al., “Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by  
292 WHO-Recommended Hand Rub Formulations and Alcohols,” *Emerg. Infect. Dis.*, vol. 26, no. 7, pp.  
293 1592–1595, 2020, doi: 10.3201/eid2607.200915.
- 294 14. M. Government, “Provincial COVID-19 Surveillance,” Winnipeg, 2020. Accessed: Nov. 30, 2021.  
295 [Online]. Available: [https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/2020/week\\_45/index.html#epi\\_curve](https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/2020/week_45/index.html#epi_curve).
- 296 15. M. Government, “Provincial COVID-19 Surveillance,” Winnipeg, 2020. Accessed: Nov. 30, 2021.  
297 [Online]. Available: [https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/2020/week\\_43/index.html](https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/2020/week_43/index.html).
- 298 16. S. Iwasaki et al., “Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva,” *J. Infect.*,  
299 vol. 81, no. 2, pp. e145–e147, 2020, doi: 10.1016/j.jinf.2020.05.071.
- 300 17. S. Wei et al., “Field-deployable, rapid diagnostic testing of saliva samples for SARS-CoV-2,” *medRxiv*  
301 Prepr. Serv. Heal. Sci., 2020, doi: 10.1101/2020.06.13.20129841.
- 302 18. K. Zhang, A. Shoukat, W. Crystal, J. M. Langley, A. P. Galvani, and S. M. Moghadas, “Routine saliva  
303 testing for the identification of silent coronavirus disease 2019 (COVID-19) in healthcare workers,” *Infect.*  
304 *Control Hosp. Epidemiol.*, vol. 42, no. 10, pp. 1189–1193, 2021, doi: 10.1017/ice.2020.1413.
- 305 19. R. Wölfel et al., “Virological assessment of hospitalized patients with COVID-2019,” *Nature*, vol. 581,  
306 no. 7809, pp. 465–469, 2020, doi: 10.1038/s41586-020-2196-x.
- 307 20. M. Hippich et al., “Public health antibody screening indicates a six-fold higher SARS-CoV-2 exposure  
308 rate than reported cases in children,” *Med*, 2020, doi: 10.1016/j.medj.2020.10.003.
- 309 21. L. M. Yonker et al., “Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection  
310 in Children,” *J. Infect. Dis.*, vol. 224, no. 11, pp. 1821–1829, Dec. 2021, doi: 10.1093/infdis/jiab509.
- 311 22. T. Jones et al., “An analysis of SARS-CoV-2 viral load by patient age,” 2020, doi:  
312 10.1101/2020.06.08.20125484.
- 313 23. C. Amaral et al., “A molecular test based on RT-LAMP for rapid, sensitive and inexpensive colorimetric  
314 detection of SARS-CoV-2 in clinical samples,” *Sci. Rep.*, vol. 11, no. 1, pp. 1–12, 2021, doi:  
315 10.1038/s41598-021-95799-6.
- 316 24. M. Government, “Provincial COVID-19 Surveillance,” Winnipeg, 2021. Accessed: Nov. 28, 2021.  
317 [Online]. Available: <https://www.gov.mb.ca/health/publichealth/surveillance/covid-19/index.html>.
- 318  
319  
320  
321